...million Investors: Accel Partners; Affymetrix Inc.; Bay City Capital; Brookside Capital Partners; Millennium Pharmaceuticals Inc.; Morgan Stanley Dean Witter...

...Discplined Growth 302,725 1.3% Edgewood 283,193 1.2% Kern Capital 252,700 1.1% Vanguard Group 252,154 1.1% Morgan Stanley Dean Witter...

...vaccine , human insulin delivery mechanisms, oral vaccine delivery, and monoclonal antibodies. In September 2000, Morgan Stanley Dean Witter...

...Number of employees: 372 Funds raised: $10.2 million Investors: State Bank of India Mutual Fund; Morgan Stanley Dean Witter...

...shares was sold at a low price on Wednesday and the stock continued to fall. Morgan Stanley Dean Witter...

...his 2001 and 2002 EPS estimates to $0.70 and $1.02 from $0.60 and $0.96, respectively. Morgan Stanley Dean Witter...

...private financing. Investors included Perseus-Soros Biopharmaceutical Fund; HealthCare Ventures; Catalyst Health & Technology Partners; and Morgan Stanley Dean Witter...

...and the other $200 million from a convertible note deal. Both deals were underwritten by Morgan Stanley Dean Witter...

...proposed a $150 million offering of convertible subordinated notes. The deals will be underwritten by Morgan Stanley Dean Witter...

...IPO. The sale brings to $39.6 million the total raised in the deal, underwritten by Morgan Stanley Dean Witter...